The Setup: Tirzepatide acts on two incretin pathways at once, the GIP and GLP-1 receptors, and while it has consistently shown benefits for heart failure hospitalization and overall mortality, its effect on broader events like heart attacks and stroke has been harder to pin down since most large trials compare it to other active drugs rather than a placebo. To get around that gap, researchers used a claims-data approach, comparing tirzepatide against sitagliptin, a diabetes drug whose cardiovascular neutrality was already established in placebo-controlled trials, effectively using it as a placebo stand-in.
The Data: Drawing on two U.S. insurance claims databases from 2022 to 2025, researchers tracked more than 52,000 adults with type 2 diabetes and existing atherosclerotic cardiovascular disease for up to a year after starting either drug. After statistically balancing the two groups, those started on tirzepatide had a one-year risk of major cardiovascular events of 2.9%, versus 4.4% for sitagliptin, a 32% lower relative hazard, driven mainly by fewer heart attacks and lower overall mortality.
The Caveats: Stroke risk didn't differ meaningfully between the two groups, and the authors flagged real limitations: a relatively short follow-up (a median of under six months on treatment), the use of an active drug as a placebo stand-in, and the usual risk of hidden bias in claims-based data. Still, the results track with earlier trial data on tirzepatide's cardiovascular benefits and give clinicians another real-world data point as its use keeps expanding beyond diabetes care.
Source: News-Medical / The British Medical Journal, Aug 10, 2026
